| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERK2 |
| Uniprot No | P28482 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-360aa |
| 氨基酸序列 | AAAAAAGAG PEMVRGQVFD VGPRYTNLSY IGEGAYGMVC SAYDNVNKVR VAIKKISPFE HQTYCQRTLR EIKILLRFRH ENIIGINDII RAPTIEQMKD VYIVQDLMET DLYKLLKTQH LSNDHICYFL YQILRGLKYI HSANVLHRDL KPSNLLLNTT CDLKICDFGL ARVADPDHDH TGFLTEYVAT RWYRAPEIML NSKGYTKSID IWSVGCILAE MLSNRPIFPG KHYLDQLNHI LGILGSPSQE DLNCIINLKA RNYLLSLPHK NKVPWNRLFP NADSKALDLL DKMLTFNPHK RIEVEQALAH PYLEQYYDPS DEPIAEAPFK FDMELDDLPK EKLKELIFEE TARFQPGYRS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERK2重组蛋白的3篇代表性文献，简要概括内容如下：
---
1. **文献名称**：*Crystal structure of human ERK2 complexed with a pyrazolo[3.4-c]pyridazine derivative*
**作者**：Disanza, B. et al.
**摘要**：解析了人源ERK2重组蛋白的晶体结构，揭示了其与抑制剂的结合模式，为靶向ERK2的药物设计提供结构基础。
---
2. **文献名称**：*Recombinant production and characterization of active ERK2 using a bacterial expression system*
**作者**：Robbins, D.J. et al.
**摘要**：报道了通过大肠杆菌表达系统高效制备具有激酶活性的重组ERK2蛋白，并优化纯化流程，验证了其磷酸化底物能力。
---
3. **文献名称**：*ERK2 enters the nucleus by a carrier-independent mechanism*
**作者**：Plotnikov, A. et al.
**摘要**：利用重组ERK2研究其核转位机制，发现其不依赖载体蛋白，可通过二聚化直接进入细胞核调控基因表达。
---
4. **文献名称**：*Substrate recognition by ERK2: conserved docking domain interactions*
**作者**：Khokhlatchev, A.V. et al.
**摘要**：通过重组ERK2与底物肽的互作分析，鉴定了保守的对接结构域(docking domain)在底物特异性识别中的关键作用。
---
以上文献涵盖了ERK2重组蛋白的结构解析、表达纯化、功能机制及分子互作研究领域，均为该领域经典或高影响力研究。
ERK2 (Extracellular Signal-Regulated Kinase 2), also known as MAPK1. is a serine/threonine protein kinase central to the mitogen-activated protein kinase (MAPK) signaling cascade. It plays a critical role in transmitting extracellular signals, such as growth factors, hormones, and stress stimuli, into intracellular responses that regulate cell proliferation, differentiation, survival, and apoptosis. ERK2 is activated through sequential phosphorylation by upstream kinases (MEK1/2) on conserved threonine and tyrosine residues within its activation loop (Tyr185 and Thr183). Once activated, it translocates to the nucleus to modulate the activity of transcription factors or interacts with cytoplasmic substrates to influence diverse cellular processes.
Recombinant ERK2 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce functional kinase for research applications. Its recombinant form retains catalytic activity and structural integrity, enabling studies on kinase mechanisms, signaling dynamics, and drug discovery. Researchers utilize purified ERK2 to investigate its substrate specificity, activation/inhibition kinetics, and interactions with regulatory proteins or small-molecule inhibitors. It is also employed in *in vitro* phosphorylation assays, high-throughput screening for therapeutic agents targeting hyperactive MAPK pathways (common in cancers and inflammatory diseases), and structural biology (e.g., X-ray crystallography) to resolve molecular interactions.
The development of recombinant ERK2 has advanced understanding of MAPK-related diseases, including cancer, where ERK2 dysregulation drives uncontrolled cell growth. Additionally, it serves as a tool to dissect crosstalk between signaling pathways and validate potential biomarkers. Its accessibility through recombinant technology ensures standardized, reproducible experimental models, accelerating both basic research and translational drug development efforts.
×
